<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880682</url>
  </required_header>
  <id_info>
    <org_study_id>2018/1511</org_study_id>
    <nct_id>NCT03880682</nct_id>
  </id_info>
  <brief_title>Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients</brief_title>
  <official_title>Treatment of Chronic Hepatitis C Virus Infection With Direct Acting Antivirals in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection, an important cause of morbidity and mortality
      worldwide, is a significant problem in kidney transplant recipients (KTRs) given its high
      prevalence in patients undergoing hemodialysis. Interferon based regimens were cornerstone of
      treatment of HCV infection in the past; however, due to their low efficacy and high rates of
      adverse effects, they have been abandoned in the new era of direct acting antivirals (DAAs).
      Several studies demonstrated the efficacy and safety of DAAs, yet data regarding clinical
      practice of these agents in KTRs is still needed. Therefore, we conducted a study using our
      registry data to evaluate the efficacy and safety of DAAs in KTRs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>6 months</time_frame>
    <description>Undetectable levels of HCV RNA for 12 weeks after the end of treatment with direct acting antivirals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable Graft Function</measure>
    <time_frame>6-12 months</time_frame>
    <description>Stability of serum creatinine and proteinuria levels of kidney transplant recipients during and after the treatment with direct acting antivirals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Serum Trough Levels of Immunosuppressive Agents</measure>
    <time_frame>6 months</time_frame>
    <description>Stability of serum trough levels of calcineurin and mTOR inhibitors during the treatment with direct acting antivirals.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients with chronic HCV infection who were treated using direct
        acting antivirals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being a kidney transplant recipient.

          -  Having a detectable level of HCV RNA.

          -  Having direct acting antivirals for 12 or 24 weeks.

        Exclusion Criteria:

          -  Withdrawing or not providing consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safak Mirioglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halil Yazici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabahattin Kaymakoglu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourli√®re M, Peck-Radosavljevic M, Manns M, Pol S. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2017 Jan 17;166(2):109-117. doi: 10.7326/M16-1205. Epub 2016 Nov 15.</citation>
    <PMID>27842383</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Safak Mirioglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>kidney transplant recipients</keyword>
  <keyword>chronic hepatitis c virus infection</keyword>
  <keyword>direct acting antivirals</keyword>
  <keyword>sofosbuvir/ledipasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

